Anti-Rheumatics Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Anti-Rheumatics Market
1.1. Definition and Scope
1.1.1. Definition of Anti-Rheumatics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Anti-Rheumatics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Anti-Rheumatics Market By Drug Class
1.2.3. Anti-Rheumatics Market By Type
1.2.4. Anti-Rheumatics Market By Distribution Channel
1.2.5. Anti-Rheumatics Market By End-User
1.2.6. Anti-Rheumatics Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Anti-Rheumatics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Anti-Rheumatics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Anti-Rheumatics Market By Drug Class
4.1. Introduction
4.2. Anti-Rheumatics Revenue By Drug Class
4.2.1. Anti-Rheumatics Revenue (USD Million) and Forecast, By Drug Class, 2020-2032
4.2.2. Disease Modifying Anti-rheumatics Drugs (DMARD’S)s
4.2.2.1. Disease Modifying Anti-rheumatics Drugs (DMARD’S) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3. Nonsteroidal Anti-inflammatory Drugs (NSAID’S)
4.2.3.1. Nonsteroidal Anti-inflammatory Drugs (NSAID’S) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.4. Corticosteroids
4.2.4.1. Corticosteroids Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.5. Uric Acid Drugs
4.2.5.1. Uric Acid Drugs Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.6. Others
4.2.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 5. Anti-Rheumatics Market By Type
5.1. Introduction
5.2. Anti-Rheumatics Revenue By Type
5.2.1. Anti-Rheumatics Revenue (USD Million) and Forecast, By Type, 2020-2032
5.2.2. Prescription-based Drugs
5.2.2.1. Prescription-based Drugs Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Over-the-counter Drugs
5.2.3.1. Over-the-counter Drugs Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Anti-Rheumatics Market By Distribution Channel
6.1. Introduction
6.2. Anti-Rheumatics Revenue By Distribution Channel
6.2.1. Anti-Rheumatics Revenue (USD Million) and Forecast, By Distribution Channel, 2020-2032
6.2.2. Retail Pharmacies
6.2.2.1. Retail Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Online Pharmacies
6.2.3.1. Online Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.4. Hospital Pharmacies
6.2.4.1. Hospital Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. Anti-Rheumatics Market By End-User
7.1. Introduction
7.2. Anti-Rheumatics Revenue By End-User
7.2.1. Anti-Rheumatics Revenue (USD Million) and Forecast, By End-User, 2020-2032
7.2.2. Hospitals & Clinics
7.2.2.1. Hospitals & Clinics Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.3. Ambulatory Surgical Centers
7.2.3.1. Ambulatory Surgical Centers Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.4. Healthcare Specialty Process
7.2.4.1. Healthcare Specialty Process Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Anti-Rheumatics Market By Country
8.1. North America Anti-Rheumatics Market Overview
8.2. U.S.
8.2.1. U.S. Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
8.2.2. U.S. Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.2.3. U.S. Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
8.2.4. U.S. Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
8.3. Canada
8.3.1. Canada Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
8.3.2. Canada Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.3.3. Canada Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
8.3.4. Canada Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Anti-Rheumatics Market By Country
9.1. Europe Anti-Rheumatics Market Overview
9.2. U.K.
9.2.1. U.K. Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
9.2.2. U.K. Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.2.3. U.K. Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.2.4. U.K. Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
9.3. Germany
9.3.1. Germany Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
9.3.2. Germany Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.3.3. Germany Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.3.4. Germany Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
9.4. France
9.4.1. France Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
9.4.2. France Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.4.3. France Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.4.4. France Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
9.5. Spain
9.5.1. Spain Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
9.5.2. Spain Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.5.3. Spain Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.5.4. Spain Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
9.6.2. Rest of Europe Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.6.3. Rest of Europe Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
9.6.4. Rest of Europe Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Anti-Rheumatics Market By Country
10.1. Asia Pacific Anti-Rheumatics Market Overview
10.2. China
10.2.1. China Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.2.2. China Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.2.3. China Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.2.4. China Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.3. Japan
10.3.1. Japan Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.3.2. Japan Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.3.3. Japan Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.3.4. Japan Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.4. India
10.4.1. India Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.4.2. India Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.4.3. India Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.4.4. India Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.5. Australia
10.5.1. Australia Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.5.2. Australia Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.5.3. Australia Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.5.4. Australia Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.6. South Korea
10.6.1. South Korea Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.6.2. South Korea Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.6.3. South Korea Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.6.4. South Korea Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
10.7.2. Rest of Asia-Pacific Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.7.3. Rest of Asia-Pacific Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
10.7.4. Rest of Asia-Pacific Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Anti-Rheumatics Market By Country
11.1. Latin America Anti-Rheumatics Market Overview
11.2. Brazil
11.2.1. Brazil Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
11.2.2. Brazil Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.2.3. Brazil Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.2.4. Brazil Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
11.3. Mexico
11.3.1. Mexico Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
11.3.2. Mexico Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.3.3. Mexico Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.3.4. Mexico Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
11.4.2. Rest of Latin America Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.4.3. Rest of Latin America Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
11.4.4. Rest of Latin America Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Anti-Rheumatics Market By Country
12.1. Middle East & Africa Anti-Rheumatics Market Overview
12.2. GCC
12.2.1. GCC Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
12.2.2. GCC Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.2.3. GCC Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.2.4. GCC Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
12.3. South Africa
12.3.1. South Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
12.3.2. South Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.3.3. South Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.3.4. South Africa Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Type, 2020-2032
12.4.2. Rest of Middle East & Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Drug Class, 2020-2032
12.4.3. Rest of Middle East & Africa Anti-Rheumatics Revenue (USD Million) and Forecast By Distribution Channel, 2020-2032
12.4.4. Rest of Middle East & Africa Anti-Rheumatics Revenue (USD Million) and Forecast By End-User, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Anti-Rheumatics Market
13.1. Anti-Rheumatics Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Anti-Rheumatics Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Johnson & Johnson
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Million), 2022
14.1.3.2. Johnson & Johnson 2022 Anti-Rheumatics Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Pfizer, Inc.
14.3. Bristol-Myers Squibb Company
14.4. Celegene Corporations
14.5. F. Hoffmann-La Roche Ltd.
14.6. MedImmune, LLC
14.7. Biogen Inc.
14.8. Celltrion Inc.
14.9. Takeda Pharmaceutical Company Ltd.
14.10. Amgen Inc.
Frequently Asked Questions
How big is the anti-rheumatics market?
The anti-rheumatics market size was valued at USD 63.2 billion in 2022.
What is the CAGR of the global anti-rheumatics market from 2023 to 2032?
The CAGR of anti-rheumatics is 2.6% during the analysis period of 2023 to 2032.
Which are the key players in the anti-rheumatics market?
The key players operating in the global market are including Johnson & Johnson, Pfizer, Inc., Bristol-Myers Squibb Company, Celegene Corporations, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Biogen Inc., Celltrion Inc., Takeda Pharmaceutical Company Ltd., and Amgen Inc.
Which region dominated the global anti-rheumatics market share?
North America held the dominating position in anti-rheumatics industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of anti-rheumatics during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global anti-rheumatics industry?
The current trends and dynamics in the anti-rheumatics industry include increasing prevalence of rheumatic diseases globally, growing adoption of biologic therapies for rheumatoid arthritis and related conditions, advancements in drug delivery systems enhancing treatment efficacy, and rising geriatric population prone to rheumatic ailments.
Which type held the maximum share in 2022?
The prescription-based drugs type the maximum share of the anti-rheumatics industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
